Annamaria Colao1, Antonella di Sarno, Rosario Pivonello
1Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, via S. Pansini 5, 80131 Naples, Italy. colao@unina.it
Cabergoline effectively treats hyperprolactinemic disorders by suppressing prolactin secretion and shrinking tumors. This ergoline derivative is well-tolerated and superior to bromocriptine, making it a preferred treatment option.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: